JMIR Publications

ABSTRACT

Background:

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD), is a major global health concern affecting over 30% of adults worldwide. Closely linked with metabolic comorbidities such as obesity, type 2 diabetes, and dyslipidemia, MASLD relies heavily on lifestyle modification for effective management. However, sustaining healthy behaviors remains challenging, specifically owing to the disease’s asymptomatic nature in its early stages and low perceived severity among patients. Thus, understanding patient perceptions and identifying barriers and facilitators are essential for developing effective, patient-centered interventions.

Objective:

This scoping review protocol aims to systematically map the existing literature on patients’ perceptions of MASLD, and to identify barriers and facilitators influencing disease management and patient engagement.

Methods:

This study will follow the Joanna Briggs Institute scoping review methodology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines. A systematic search is conducted in PubMed (MEDLINE), CINAHL, Cochrane Library, and PsycINFO using MeSH terms and keywords such as “MASLD,” “NAFLD,” “perception,” “awareness,” “attitude,” “barriers,” and “facilitators." Two independent reviewers screen studies, extract data using a standardized charting form, and resolve discrepancies through discussion or consultation with a third reviewer. Eligible studies will include adults with MASLD/NAFLD and will focus on patient perceptions, health beliefs, behaviors, or barriers and facilitators to management. Findings will be synthesized narratively and presented in both textual and table formats.

Results:

The results will be reported in a forthcoming scoping review, which is expected to be submitted for publication in a peer-reviewed journal by early 2026.

Conclusions:

This study will offer a comprehensive overview of patients’ perceptions of MASLD, and the barriers and facilitators that influence its management. The findings will inform the development of patient-centered strategies aimed at improving care delivery and reducing disease burden.